Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: A critical review

Circulation

Volumn 94, Issue 11, 1996, Pages 3026-3049

  Weitz, Jeffrey I ^a   Byrne, John ^a   Patrick Clagett, G ^a   Farkouh, Michael E ^a   Porter, John M ^a   Sackett, David L ^a   Eugene Strandness Jr , D ^a   Taylor, Lloyd M ^a  

^a AMERICAN HEART ASSOCIATION   (United States)

Author keywords

aging; AHA Medical Scientific Statements; claudication; ischemia; peripheral vascular disease

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ACETYLSALICYLIC ACID; KETANSERIN; PENTOXIFYLLINE; VASODILATOR AGENT;

DRUG EFFICACY; FIBRINOLYTIC THERAPY; HUMAN; LIMB BLOOD FLOW; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0029850227     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.11.3026     Document Type: Review

References (294)

1. Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand. 1982; 211:249-256.
2. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen KH, Schroeder T. Fate in intermittent claudication: outcome and risk factors. Br Med J (Clin Res Ed). 1986;293:1137-1140.
3. Criqui MH, Fronek A, Barrett-Conner E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71:510-515.
4. Imparato AM, Kim GE, Davidson T, Crowley JG. Intermittent claudication: its natural course. Surgery. 1975;78:795-799.
5. Cronenwett JL, Warner KG, Zelenock GB, Whitehouse WM Jr, Graham LM, Lindenauer M, Stanley JC. Intermittent claudication: current results of nonoperative management. Arch Surg. 1984;119: 430-436.
6. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
7. Boissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Haemost. 1989;62:681-685.
8. Katsumura T, Mishima Y, Kamiya K, Sakaguchi S, Tanabe T, Sakuma A. Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation on chronic arterial occlusive diseases: a double-blind study versus placebo. Angiology. 1982;33:357-367.
9. Arcan JC, Panak E. Ticlopidine in the treatment of peripheral occlusive arterial disease. Semin Thromb Hemost. 1989;15:167-170.
10. Balsano F, Coccheri S, Libretti A, Nenci GG, Catalano M, Fortunato G, Grasselli S, Violi F, Hellemans H, Vanhove P. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med. 1989;114:84-91.
11. Second European Consensus Document on chronic critical leg ischemia. Eur J Vasc Surg. 1992;6(suppl A):1-32.
12. Criqui MH, Fronek A, Klauber MR, Barrett-Connor E, Gabriel S. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral disease: results from noninvasive testing in a defined population. Circulation. 1985;71:516-522.
13. Gofin R, Kark JD, Friedlander Y, Lewis BS, Witt H, Stein Y, Gotsman MS. Peripheral vascular disease in a middle-aged popu- lation sample: the Jerusalem Lipid Research Clinic Prevalence Study. Isr J Med Sci. 1987;23:157-167.
14. Beach KW, Strandness DE Jr. Arteriosclerosis obliterans and associated risk factors in insulin-dependent and non-insulin-dependent diabetes. Diabetes. 1980;29:882-888.
15. Ouriel K, McDonnell AE, Metz CE, Zarins CK. A critical evaluation of stress testing in the diagnosis of peripheral vascular disease. Surgery. 1982;91:686-693.
16. Carter SA. Clinical measurement of systolic pressures in limbs with arterial occlusive disease. JAMA. 1969;207:1869-1874.
17. Fowkes FGR, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20:384-392.
18. Wilt TJ. Current strategies in the diagnosis and management of lower extremity peripheral vascular disease. J Gen Intern Med. 1992;7:87-101.
19. Leng GC, Fowkes FGE. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol. 1992;45:1101-1109.
20. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc. 1985;33:13-18.
21. Schroll M, Munck O. Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurements in a population study of 60-year-old men and women. J Chronic Dis. 1981;34:261-269.
22. Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blomberg P, Bousser MG, Clement D, Coffman J, Deutshinoff A, et al. Fate of the patient with chronic leg ischaemia: a review article. J Cardiovasc Surg (Torino). 1989;30:50-57.
23. Vogt MT, Wolfson SK, Kuller LH. Lower extremity arterial disease and the aging process: a review. J Clin Epidemiol. 1992;45:529-542.
24. Dormandy J. Peripheral vascular disease. Med North Am. 1994; 353-360.
25. Widmer LK, Biland L, DaSilva A. Risk profile and occlusive periphery artery disease (OPAD). In: Proceedings of the 13th International Congress of Angiology; June 1985; Athens, Greece; 28.
26. Stout RW. Diabetes, atherosclerosis and aging. Diabetes Care. 1990;13(suppl 2):20-23.
27. Gordon T, Kannel WB. Predisposition to atherosclerosis in the head, heart, and legs: the Framingham study. JAMA. 1972;221:661-666.
28. Farkouh ME, Rihal CS, Gersh BJ, Rooke TW, Hallett JW Jr, O'Fallon WM, Ballard DJ. Influence of coronary heart disease on morbidity and mortality after lower extremity revaseularization surgery: a population-based study in Olmsted County, Minnesota (1970-1987). J Am Coll Cardiol. 1994;24:1290-1296.
29. Jonason T, Ringqvist I. Factors of prognostic importance for subsequent rest pain in patients with intermittent claudication. Acta Med Scand. 1985;218:27-33.
30. Hughson WG, Mann JI, Garrod A. Intermittent claudication: prevalence and risk factors. Br Med J. 1978;1:1379-1381.
31. Criqui MH, Browner D, Fronek A, Klauber MR, Coughlin SS, Barrett-Connor E, Gabriel S. Peripheral arterial disease in large vessels is epidemiologically distinct from small vessel disease: an analysis of risk factors. Am J Epidemiol. 1989;129:1110-1119.
32. Gown AM, Tsukada T, ROSS R. Human atherosclerosis, II: immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol. 1986;125:191-207.
33. Kannel WB, Shurtleff D. The Framingham Study: cigarettes and the development of intermittent claudication. Geriatrics. 1973;28: 61-68.
34. DePalma RG. Patterns of peripheral atherosclerosis: implications for treatment. In: Shepherd JT, Morgan HG, Packard CJ, Brownlie SM, eds. Atherosclerosis: Developments. Complications and Treatment: Proceedings of the International Symposium. Gleneagles Hotel, Perthshire, Scotland, April 23-26, 1987. New York, NY: Elsevier Science Publishing Co; 1987:161-174.
35. Kannel WB, Skinner JJ Jr, Schwartz MJ, Shurtleff D. Intermittent claudication: incidence in the Framingham Study. Circulation. 1970;41:875-883.
36. Zimmerman BR, Palumbo PJ, O'Fallon WM, Ellefson RD, Osmundson PJ, Kazmier FJ. A prospective study of peripheral occlusive arterial disease in diabetes. III: initial lipid and lipoprotein findings. Mayo Clinic Proc. 1981;56:233-242.
37. Duffield RGM, Lewis B, Miller NE, Jamieson CW, Brunt JN, Colchester AC. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis: a randomised controlled trial. Lancet. 1983;2:639-642.
38. The Lipid Research Clinics Coronary Primary Prevention Trial resuits, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
39. McDaniel MD, Cronenwett JL. Basic data related to the natural history of intermittent claudication. Ann Vasc Surg. 1989;3: 273-277.
40. Peabody CN, Kannel WB, McNamara PM. Intermittent claudication: surgical significance. Arch Surg. 1974;109:693-697.
41. Danish Amputation Register, Herlev Hospital, Copenhagen, 1989.
42. Most RS, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care. 1983;6:87-91.
43. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA. 1993;270:465-469.
44. Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA. 1993;270:487-489.
45. Marinelli MR, Beach KW, Glass MJ, Primozich JF, Strandness DE Jr. Noninvasive testing vs clinical evaluation of arterial disease: a prospective study. JAMA. 1979;241:2031-2034.
46. Strandness DE Jr, Priest RR, Gibbons GE. A combined clinical and pathological study of nondiabetic and diabetic vascular disease. Diabetes. 1964;13:366-372.
47. Gensler SW, Haimovici H, Hoffert P, Steinman C, Beneventano TC. Study of vascular lesions in diabetic, non-diabetic patients. Arch Surg. 1965;91:617-622.
48. Wheelock FC Jr. Transmetatarsal amputation and arterial surgery in diabetic patients. N Engl J Med. 1961;264:316-320.
49. Lindbom A. Arteriosclerosis and arterial thrombosis in the lower limb: a roentgenological study. Acta Radiol Scand. 1950;80(suppl): 38-48.
50. Strandness DE Jr, Bell JW. Peripheral vascular disease: diagnosis and objective evaluation using a mercury strain gauge. Ann Surg. 1965;161 (suppl):1-35.
51. Sumner DS, Strandness DE Jr. The relationship between calf blood flow and ankle blood pressure in patients with intermittent claudication. Surgery. 1969;65:763-771.
52. Strandness DE Jr, Schultz RD, Sumner DS, Rushmer RF. Ultrasonic flow detection: a useful technic in the evaluation of peripheral vascular disease. Am J Surg. 1967;113:311-320.
53. Strandness DE Jr. Exercise testing in the evaluation of patients undergoing direct arterial surgery. J Cardiovasc Surg (Torino). 1970; 11:192-200.
54. Strandness DE Jr, Bell JW. Ankle pressure responses after reconstructive arterial surgery. Surgery. 1966;59:514-516.
55. Strandness DE Jr. Hemodynamics of the normal arterial and venous system. In: Strandness DE Jr, ed. Duplex Scanning in Vascular Disorders. New York, NY: Raven Press; 1993:45-79.
56. Stahler C, Strandness DE Jr. Ankle blood pressure response to graded treadmill exercise. Angiology. 1967;18:237-241.
57. Skinner JS, Strandness DE Jr. Exercise and intermittent claudication. I: effect of repetition and intensity of exercise. Circulation. 1967;36:15-22.
58. Beach KW, Brunzell JD, Strandness DE Jr. Prevalence of severe arteriosclerosis obliterans in patients with diabetes mellitus: relation to smoking and form of therapy. Arteriosclerosis. 1982;2:275-280.
59. Holstein P, Lassen NA. Healing of ulcers on the feet correlated with distal blood pressure measurements in occlusive arterial disease. Acta Orthop Scand. 1980;51:995-1006.
60. Orchard TJ, Strandness DE Jr. Assessment of peripheral vascular disease in diabetes: report and recommendations of an international workshop sponsored by the American Diabetes Association and the American Heart Association, September 18-20, 1992, New Orleans, Louisiana. Circulation. 1993;88:819-828.
61. Raines JK. The pulse volume recorder in peripheral arterial disease. In: Berstein EF, ed. Vascular Diagnosis. 4th ed. St Louis, Mo: CV Mosby Co; 1993:534-543.
62. Strandness DE Jr. Peripheral arterial system. In: Duplex Scanning in Vascular Disorders. 2nd ed. New York, NY: Raven Press; 1993:159-195.
63. Barber FE, Baker DW, Strandness DE Jr. Duplex scanner II for simultaneous imaging of artery tissues and flow. In: Proceedings of Ultrasonics Symposium, IEEE, 1974. Publication No. 74CH0896-ISU.
64. Phillips DJ, Powers JE, Eyer MK, Blackshear WM Jr, Bodily KC, Strandness DE Jr, Baker DW. Detection of peripheral vascular disease using the Duplex Scanner III. Ultrasound Med Biol. 1980; 6:205-218.
65. Jager KA, Phillips DJ, Martin RL, Hanson C, Roederer GO, Langlois YE, Ricketts HJ, Strandness DE Jr. Noninvasive mapping of lower limb arterial lesions. Ultrasound Med Biol. 1985;11:515-521.
66. Kohler TR, Andros G, Porter JM, Clowes A, Goldstone J, Johansen K, Raker E, Nance DR, Strandness DE Jr. Can duplex scanning replace arteriography for lower extremity arterial disease? Ann Vasc Surg. 1990;4:280-287.
67. Kohler TR, Nance DR, Cramer MM, Vandenburghe N, Strandness DE Jr. Duplex scanning for diagnosis of aortoiliac and femoro-popliteal disease: a prospective study. Circulation. 1987;76: 1074-1080.
68. May AG, Vandeberg L, DeWeese JA, Rob DG. Critical arterial stenosis. Surgery. 1963;54:250-259.
69. Carter SA. Response of ankle systolic pressure to leg exercise in mild or questionable arterial disease. N Engl J Med. 1972;287: 578-582.
70. Legemate DA, Teeuwen C, Hoeneveld H, Ackerstaff RGA, Eikelboom BC. The potential for duplex scanning to replace aorto-iliac and femoro-popliteal angiography. Eur J Vasc Surg. 1989;3:49-54.
71. Hatsukami TS, Primozich J, Zierler RE, Strandness DE Jr. Color Doppler characteristics in normal lower extremity arteries. Ultrasound Med Biol. 1992;18:167-171.
72. Hatsukami TS, Primozich JF, Zierler RE, Harley JD, Strandness DE Jr. Color Doppler imaging of infrainguinal arterial occlusive disease. J Vasc Surg. 1992;16:527-533.
73. Edwards JM, Coldwell DM, Goldman ML, Strandness DE Jr. The role of duplex scanning in the selection of patients for transluminal angioplasty. J Vasc Surg. 1991;13:69-74.
74. Bandyk DF, Schmitt DD, Seabrook GR, Adams MB, Towne JB. Monitoring functional patency of in situ saphenous vein bypasses: the impact of a surveillance protocol and elective revision. J Vasc Surg. 1989;9:286-296.
75. Bandyk DF. Postoperative surveillance of infrainguinal bypass. Surg Clin North Am. 1990;70:71-85.
76. Mattos MA, van Bemmelen PS, Hodgson KJ, Ramsey DE, Barkmeier LD, Sumner DS. Does correction of stenoses identified with color duplex scanning improve infrainguinal graft patency? J Vasc Surg. 1993;17:54-66.
77. Lundell A, Lindblad B, Bergqvist D, Hansen F. Femoropoplitealcrural graft patency is improved by an intensive surveillance program: a prospective randomized study. J Vasc Surg. 1995;21:26-33.
78. Strandness DE Jr, Andros G, Baker JD, Bernstein EF. Vascular laboratory utilization and payment: report of the Ad Hoc Committee of the Western Vascular Society. J Vasc Surg. 1992;16:163-170.
79. Applegate WB. Ankle/arm blood pressure index: a useful test for clinical practice? JAMA. 1993;270:497-498. Editorial.
80. Vogt MT, McKenna M, Anderson SJ, Wolfson SK, Kuller LH. The relationship between ankle-arm index and mortality in older men and women. J Am Geriatr Soc. 1993;41:523-530.
81. Taylor LM Jr, Porter JM. Natural history and non-operative treatment of chronic lower extremity ischemia. In: Rutherford RB, ed. Vascular Surgery. 3rd ed. Philadelphia, Pa: WB Saunders; 1989:653-667.
82. Joyce JW. Non-operative, non-pharmacologic management of lower extremity occlusive disease. In: Ernst CB, Stanley JC, eds. Current Therapy in Vascular Surgery. 2nd ed. Philadelphia, PA: BC Decker; 1991:550-552.
83. Verhaeghe R, Bounameaux H. Peripheral arterial occlusion: thromboembolism and antithrombotic therapy. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, Pa: WB Saunders; 1992:423-449.
84. Ernst E, Fialka V. A review of the clinical effectiveness of exercise therapy for intermittent claudication. Arch Intern Med. 1993;153: 2357-2360.
85. Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med. 1990;113:135-146.
86. Larsen OA, Lassen NA. Effect of daily muscular exercise in patients with intermittent claudication. Lancet. 1966;2:1093-1096.
87. Ericsson B, Haeger K, Lindell SE. Effect of physical training on intermittent claudication. Angiology. 1970;21:188-192.
88. Dahllof AG, Holm J, Schersten T, Sivertsson R. Peripheral arterial insufficiency: effect of physical training on walking tolerance, calf blood flow, and blood flow resistance. Scand J Rehabil Med. 1976;8:19-26.
89. Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation. 1990;81:602-609.
90. Holm J, Dahllof AG, Bjorntorp P, Schersten T. Enzyme studies in muscles of patients with intermittent claudication: effect of training. Scand J Clin Lab Invest Suppl. 1973;128:201-205.
91. Dahllof AG, Bjorntorp P, Holm J, Schersten T. Metabolic activity of skeletal muscle in patients with peripheral arterial insufficiency. Eur J Clin Invest. 1974;4:9-15.
92. Mannarino E, Pasqualini L, Menna M, Maragoni G, Orlandi U. Effects of physical training on peripheral vascular disease: a controlled study. Angiology. 1989;40:5-10.
93. Ernst EE, Matrai A. Intermittent claudication, exercise, and blood rheology. Circulation. 1981;76:1110-1114.
94. Lundgren F, Dahllof AG, Lundholm K, Schersten T, Volkmann R. Intermittent claudication: surgical reconstruction or physical training? A prospective randomized trial of treatment efficiency. Ann Surg. 1989;209:346-355.
95. Jonason T, Jonzon B, Ringqvist I, Oman-Rydberg A. Effect of physical training on different categories of patients with intermittent claudication. Acta Med Scand 1979;206:253-258.
96. Rosfors S, Bygdeman S, Arnetz BB, Lahnborg G, Skoldo L, Eneroth P, Kallner A. Longterm neuroendocrine and metabolic effects of physical training in intermittent claudication. Scand J Rehabil Med. 1989;21:7-11.
97. Skinner JS, Strandness DE Jr. Exercise and intermittent claudication, II: effect of physical training. Circulation. 1967;36:23-29.
98. Alpert SJ, Larsen OA, Lassen NA. Exercise and intermittent claudication: blood flow in the calf muscle during walking studied by the xenon-133 clearance method. Circulation. 1969;39:353-359.
99. Lepantalo M, Sundberg S, Gordin A. The effects of physical training and flunarizine on walking capacity in intermittent claudication. Scand J Rehabil Med. 1984;16:159-162.
100. Blumchen G, Landry F, Kiefer H, Schlosser V. Hemodynamic responses of claudicating extremities: evaluation of a long range exercise program. Cardiology. 1970;55:114-127.
101. Jonason T, Ringqvist I. Effect of training on the post-exercise ankle blood pressure reaction in patients with intermittent claudication. Clin Physiol. 1987;7:63-69.
102. Jonason T, Ringqvist I. Prediction of the effect of training on the walking tolerance in patients with intermittent claudication. Scand J Rehabil Med. 1987;19:47-50.
103. Jonason T, Ringqvist I, Oman-Rydberg A. Home-training of patients with intermittent claudication. Scand J Rehabil Med. 1981; 13:137-141.
104. Policy WT. Treatment of gangrene of the feet and legs by walking. Circulation. 1957;15:670-689.
105. Sorlie D, Myhre K. Effects of physical training in intermittent claudication. Scand J Clin Lab Invest. 1978;38:217-222.
106. Clifford PC, Davies PW, Hayne JA, Baird RN. Intermittent claudication: is a supervised exercise class worthwhile? Br Med J. 1980;280:1503-1505.
107. Hall J, Barnard R. The effects of an intensive 26-day program of diet and exercise on patients with peripheral vascular disease. J Cardiac Rehabil. 1982;2:569-574.
108. Hedberg B, Langstrom M, Angquist KA, Fugl-Meyer AR. Isokinetic plantar flexor performance and fatiguability in peripheral arterial insufficiency. Acta Chir Scand. 1988;154:363-369.
109. Andriessen MPHM, Barendsen GJ, Wouda AA, de Pater L. Changes of walking distance in patients with intermittent claudication during six months intensive physical training. Vasa. 1989;18:63-68.
110. Ruell PA, Imperial ES, Bonar FJ, Thursby PF, Gass GC. Intermittent claudication: the effect of physical training on walking tolerance and venous lactate concentration. Eur J Appl Physiol. 1984; 52:420-425.
111. Carter SA, Hamel ER, Paterson JM, Snow CJ, Mymin D. Walking ability and ankle systolic pressures: observations in patients with intermittent claudication in a short-term walking exercise program. J Vasc Surg. 1989;10:642-649.
112. Williams LR, Ekers MA, Collins PS, Lee JF. Vascular rehabilitation: benefits of a structured exercise/risk modification program. J Vasc Surg. 1991;14:320-326.
113. Feinberg RL, Gregory RT, Wheeler JR, Snyder SO Jr, Gayle RG, Parent FN III, Patterson RB. The ischemic window: a method for the objective quantitation of the training effect in exercise therapy for intermittent claudication. J Vasc Surg. 1992;16:244-250.
114. Hiatt WR, Regensteiner JG. Exercise rehabilitation in the treatment of patients with peripheral arterial disease. J Vasc Med Biol. 1990; 2:163-170.
115. Johnson EC, Voyles WF, Atterbom HA, Pathak D, Sutton MF, Greene ER. Effects of exercise training on common femoral artery blood flow in patients with intermittent claudication. Circulation. 1989;80(suppl 3, pt 2):III-59-III-72.
116. Schoop W. Mechanism of beneficial action of daily walking training of patients with intermittent claudication. Scand J Clin Lab Invest Suppl. 1973;128:197-199.
117. Zetterquist S. The effect of active training on the nutritive blood flow in exercising ischemic legs. Scand J Clin Lab Invest. 1970; 25:101-111.
118. Greenspan K, Lawrence PF, Esposito DB, Voorhees AB. The role of biofeedback and relaxation therapy in arterial occlusive disease. J Surg Res. 1980;29:387-394.
119. Henriksson J, Nygaard E, Andersson J, Eklof B. Enzyme activities, fibre types and capillarization in calf muscles of patients with intermittent claudication. Scand J Clin Lab Invest. 1980;40:361-369.
120. Hughson WG, Mann JI, Tibbs DJ, Woods HF, Walton I. Intermittent claudication: factors determining outcome. Br Med J. 1978;1: 1377-1379.
121. Juergens J, Barker H, Hines E. Atherosclerosis obliterans: review of 520 cases with special reference to pathogenic and prognostic factors. Circulation. 1960;21:188-195.
122. Jonason T, Ringqvist I. Factors of prognostic importance for subsequent rest pain in patients with intermittent claudication. Acta Med Scand. 1985;218:27-33.
123. Myers KA, King RB, Scott DF, Johnson N, Morris PJ. The effect of smoking on the late patency of arterial reconstructions in the legs. Br J Surg. 1978;65:267-271.
124. Robicsek F, Daugherty HK, Mullen DC, Masters TN, Narbay D, Sanger PW. The effect of continued cigarette smoking on the patency of synthetic vascular grafts in Leriche syndrome. J Thorac Cardiovasc Surg. 1975;70:107-113.
125. Ameli FM, Stein M, Provan JL, Presser R. The effect of postoperative smoking on femoropopliteal bypass grafts. Ann Vasc Surg. 1989;3:20-25.
126. Lassila R, Lepantalo M. Cigarette smoking and the outcome after lower limb arterial surgery. Acta Chir Scand. 1988;154:635-640.
127. Greenhalgh RM, Laing SP, Cole PV, Taylor GW. Smoking and arterial reconstruction. Br J Surg. 1981;68:605-607.
128. Herring M, Gardner A, Glover J. Seeding human arterial prostheses with mechanically derived endothelium: the detrimental effect of smoking. J Vasc Surg. 1984;1:279-289.
129. Birkenstock WE, Louw JH, Terblanche J, Immelman EJ, Dent DM, Baker PM. Smoking and other factors affecting the conservative management of peripheral vascular disease. S Afr Med J. 1975; 49:1129-1132.
130. Quick CRG, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg. 1982;69(suppl):S24-S26.
131. Coffman JD. Vasodilator drugs in peripheral vascular disease. N Engl J Med. 1979;301:159-160. Letter.
132. Reid HL, Dormandy JA, Barnes AJ, Lock PJ, Dormandy TL. Impaired red cell deformability in peripheral vascular disease. Lancet. 1976;1:666-668.
133. Dormandy JA, Hoare E, Colley J, Arrowsmith DE, Dormandy TL. Clinical, haemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication. Br Med J. 1973;4: 576-581.
134. Ehrly AM. Improvement of the flow properties of blood: a new therapeutical approach in occlusive arterial disease. Angiology. 1976;27:188-196.
135. Angelkort B, Maurin N, Boateng K. Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease. Curr Med Res Opin. 1979;6:255-258.
136. Johnson WC, Sentissi JM, Baldwin D, Hamilton J, Dion J. Treatment of claudication with pentoxifylline: are benefits related to improvement in viscosity? J Vasc Surg. 1987;6:211-216.
137. Angelkort B, Kiesewetter H. Influence of risk factors and coagulation phenomena on the fluidity of blood in chronic arterial occlusive disease. Scand J Clin Lab Invest Suppl. 1981;156:185-188.
138. Accetto B. Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: results of double-blind study versus vasodilator-nylidrin. Am Heart J. 1982;103:864-869.
139. Bollinger A, Frei C. Double blind study of pentoxifylline against placebo in patients with intermittent claudication. Pharmatherapeutica. 1977;1:557-562.
140. Di Perri T, Guerrini M. Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication. Angiology. 1983;34:40-45.
141. Roekaerts F, Deleers L. Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration. Angiology. 1984;35:396-406.
142. Strano A, Davi G, Avellone G, Novo S, Pinto A. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology. 1984;35:459-466.
143. Lindgarde F, Jelnes R, Bjorkman H, Adielsson G, Kjellstrom T, Palmquist I, Stavenow L. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease: Scandinavian Study Group. Circulation. 1989;80:1549-1556.
144. Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT, Strandness DE. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J. 1982;104:66-72.
145. Dettori AG, Pini M, Moratti A, Paolicelli M, Basevi P, Quintavalla R, Manotti C, Di Lecce C. Acenocoumarol and pentoxifylline in intermittent claudication: a controlled clinical study: the APIC study group. Angiology. 1989;40(pt 1):237-248.
146. Gallus AS, Gleadow F, Dupont P, Walsh J, Morley AA, Wenzel A, Alderman M, Chivers D. Intermittent claudication: a double-blind crossover trial of pentoxifylline. Aust N Z J Med. 1985;15:402-409.
147. Perhoniemi V, Salmenkivi K, Sundberg S, Johnsson R, Gordin A. Effects of flunarizine and pentoxifylline on walking distance and blood rheology in claudication. Angiology. 1984;35:366-372.
148. Reilly DT, Quinton DN, Barrie WW. A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and Theological effects. N Z Med J. 1987;100:445-447.
149. Tonak J, Knecht H, Groitl H. Treatment of circulatory disturbances with pentoxifylline: a double blind study with Trental. Pharmatherapeutica. 1983;3(suppl 1):126-135.
150. PACK Claudication Substudy. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants: changes in claudication distance and ankle systolic pressure. Circulation. 1989;80:1544-1548.
151. Verhaeghe R, Van Hoof A, Beyens G. Controlled trial of suloctidil in intermittent claudication. J Cardiovasc Pharmacol. 1981;3: 279-286.
152. Creager MA, Roddy MA. The effect of nifedipine on calf blood flow and exercise capacity in patients with intermittent claudication. J Vasc Med Biol. 1990;2:94-99.
153. Gans ROB, Bilo HJG, Weersink EGL, Rauwerda JA, Fonk T, Popp-Snijders C, Donker AJM. Fish oil supplementation in patients with stable claudication. Am J Surg. 1990;160:490-495.
154. Clyne CA, Galland RB, Fox MJ, Gustave R, Jantet GH, Jamieson CW. A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication. Br J Surg. 1980;67:347-348.
155. Greenhalgh RM. Naftidrofuryl for ischemic rest pain: a controlled trial. Br J Surg. 1981;68:265-266.
156. Guldager B, Jelnes R, Jorgensen SJ, Nielsen JS, Klaerke A, Mogensen K, Larsen KE, Reimer E, Holm J, Ottesen S. EDTA treatment of intermittent claudication: a double-blind, placebo-controlled study. J Intern Med. 1992;231:261-267.
157. van Rij AM, Solomon C, Packer SGK, Hopkins WG. Chelation therapy for intermittent claudication: a double-blind, randomized, controlled trial. Circulation. 1994;90:1194-1199.
158. Brevetti G, Chiariello M, Ferulano G, Policicchio A, Nevola E, Rossini A, Attisano T, Ambrosio G, Siliprandi N, Angelini C. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation. 1988;77:767-773.
159. Ernst E, Matrai A, Kollar L. Placebo-controlled, double-blind study of haemodilution in peripheral arterial disease. Lancet. 1987;1: 1449-1451.
160. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: a prospective double-blind arteriographically controlled trial. Lancet. 1985;1:415-419.
161. Goldhaber SZ, Manson JE, Stampfer MJ, LaMotte F, Rosner B, Buring JE, Hennekens CH. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet. 1992;340:143-145.
162. Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW. Aspirin and other platelet-active drugs: the relationship between dose, effectiveness, and side effects. Chest. 1992;102(suppl 4):327S-336S.
163. Clagett GP, Graor RA, Salzman EW. Antithrombotic therapy in peripheral arterial occlusive disease. Chest. 1992;102(suppl 4): 516S-528S.
164. Fuster V, Chesebro JH. Role of platelets and platelet inhibitors in aortocoronary artery vein-graft disease. Circulation. 1986;73: 227-232.
165. Boobis LH, Bell PR. Can drugs help patients with lower limb ischaemia? Br J Surg. 1982;69(suppl):S17-S23.
166. Coffman JD. Intermittent claudication and rest pain: physiologic concepts and therapeutic approaches. Prog Cardiovasc Dis. 1979; 22:53-72.
167. Tillgren C. Obliterative arterial disease of the lower limbs, IV: evaluation of long-term anticoagulant therapy. Acta Med Scand. 1965; 178:203.
168. Jones NAG, De Haas H, Zahavi J, Kakkar VV. A double-blind trial of suloctidil v placebo in intermittent claudication. Br J Surg. 1982;69:38-40.
169. Antiplalelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed). 1988;296:320-331.
170. 1 infusions in occlusive arterial disease stage III/IV. Vasa Suppl. 1989;28:31-38.
171. Schuler JJ, Flanigan DP, Holcroft JW, Ursprung JJ, Mohrland JS, Pyke J. Efficacy of prostaglandin E, in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease: results of a prospective randomized, double-blind, multi-center clinical trial. J Vasc Surg. 1984;1:160-170.
172. Nizankowski R, Krolikowski W, Bielatowicz J, Szczeklik A. Prostacyclin for ischemic ulcers in peripheral arterial disease: a random assignment, placebo controlled study. Thromb Res. 1985;37:21-28.
173. Belch JJF, McKay A, McArdle B, Leiberman P, Pollock JG, Lowe GD, Forbes CD, Prentice CR. Epoprostenol (prostacyclin) and severe arterial disease: a double-blind trial. Lancet. 1983;1:315-317.
174. Cronenwett JL, Zelenock GB, Whitehouse WM Jr, Lindenauer SM, Graham LM, Stanley JC. Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructible peripheral arterial occlusive disease. Surgery. 1986;100:369-375.
175. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
176. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333:1301-1307.
177. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients: Harvard Atherosclerosis Reversibility Project (HARP) Group. Lancet. 1994;334: 1182-1186.
178. Johnston KW. Aortoiliac disease treatment: a surgical comment. Circulation. 1991;83(suppl I):I-61-I-62.
179. Wolf GL, Wilson SE, Cross AP, Deupree RH, Stason WB, for the principal investigators and their associates of Veterans Administration Cooperative Study Number 199. Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial. J Vasc Interv Radiol. 1993;4:639-648.
180. Casarella WJ. Noncoronary angioplasty. Curr Probl Cardiol. 1986; 11:141-174.
181. Johnston KW, Rae M, Hogg-Johnston SA, Colapinto RF, Walker PM, Baird RJ, Sniderman KW, Kalman P, Five-year results of a prospective study of percutaneous transluminal angioplasty. Ann Surg. 1987;206:403-413.
182. Tegtmeyer CJ, Hartwell GD, Selby JB, Robertson R Jr, Kron IL, Tribble CG. Results and complications of angioplasty in aortoiliac disease. Circulation. 1991;83(suppl I):I-53-I-60.
183. Stokes KR, Strunk HM, Campbell DR, Gibbons GW, Wheeler KG, Clouse ME. Five-year results of iliac and femoropopliteal angioplasty in diabetic patients. Radiology. 1990:174(pt 2):977-982.
184. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty: factors influencing long-term success. Circulation. 1991; 83(suppl I):I-70-I-80.
185. Hunink MGM, Wong JB, Donaldson MC, Meyerovitz MF, de Vries J, Harrington DP. Revascularization for femoropopliteal disease: a decision and cost-effectiveness analysis. JAMA. 1995;274:165-171.
186. Currie IC, Wakeley CJ, Cole SEA, Wyatt MG, Scott DJA, Baird RN, Horrocks M. Femoropopliteal angioplasty for severe limb ischaemia. Br J Surg. 1994;81:191-193.
187. Schwarten DE. Clinical and anatomical considerations for non-operative therapy in tibial disease and the results of angioplasty. Circulation. 1991;83(suppl I):I-86-I-90.
188. Tunis SR, Bass EB, Steinberg EP. The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease. N Engl J Med. 1991;325:556-562.
189. Enzler MA. Failure of an increased number of revascularization procedures to decrease the rate of lower-extremity amputations. Radiology. 1994;190:904-905. Letter.
190. Pell JP, Whyman MR, Fowkes FGR, Gillespie I, Ruckley CV. Trends in vascular surgery since the introduction of percutaneous transluminal angioplasty. Br J Surg. 1994;81:832-835.
191. Hasson JE, Archer CW, Wojtowycz M, McDermott J, Crummy A, Turnipseed WD. Lower extremity percutaneous transluminal angioplasty: multifactorial analysis of morbidity and mortality. Surgery. 1990;108:748-754.
192. Cooper JC, Welsh CL. The role of percutaneous transluminal angioplasty in the treatment of critical ischaemia. Eur J Vasc Surg. 1991;5:261-264.
193. Strecker EP, Hagen B, Liermann D, Schneider B, Wolf HR, Wambsganss J. Iliac and femoropopliteal vascular occlusive disease treated with flexible tantalum stents. Cardiovasc Intervent Radiol. 1993;16:158-164.
194. Bonn J, Gardiner GA Jr, Palmaz J, Shapiro MJ, Sullivan KL, Levin DC. Improved angioplasty hemodynamics after Palmaz vascular stem placement. Circulation. 1989;80(suppl II):II-411. Abstract.
195. Becker GJ, Palmaz JC, Rees CR, Ehrman KO, Lalka SG, Dalsing MC, Cikrit DF, McLean GK, Burke DR, Richter GM, et al. Angioplasty-induced dissections in human iliac arteries: management with Palmaz balloon-expandable intraluminal stents. Radiology. 1990; 176:31-38.
196. Amery A, Deloof W, Vermylen J, Verstraete M. Outcome of recent thromboembolic occlusions of limb arteries treated with streptokinase. BMJ. 1970;4:639-644.
197. Dotter CT, Rosch J, Seaman AJ, Dennis D, Massey WH. Streptokinase treatment of thromboembolic disease. Radiology. 1972;102: 283-290.
198. Dotter CT, Rosch J, Seaman AJ. Selective clot lysis with low-dose streptokinase. Radiology. 1974;111:31-37.
199. Comerota AJ, Conen GS. Thrombolytic therapy in peripheral arterial occlusive disease: mechanisms of action and drugs available. Can J Surg. 1993;36:342-348.
200. Martin M, Fiebach BJ. Short-term ultrahigh streptokinase treatment of chronic arterial occlusions and acute deep vein thromboses. Semin Thromb Hemost. 1991;17:21-38.
201. McNamara TO, Fischer JR. Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase. AJR Am J Roentgenol. 1985;144:769-775.
202. McNamara TO. Role of thrombolysis in peripheral arterial occlusion. Am J Med. 1987;83:6-10.
203. Berridge DC, Gregson RH, Makin GS, Hopkinson BR. Tissue plasminogen activator in peripheral arterial thrombolysis. Br J Surg. 1990;77:179-182.
204. Berridge DC, Gregson RH, Hopkinson BR, Makin GS. Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis, Br J Surg. 1991;78:988-995.
205. Meyerovitz MF, Goldhaber SZ, Reagan K, Polak JF, Kandarpa K, Grassi CJ, Donovan BC, Bettmann MA, Harrington DP. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology. 1990;175:75-78.
206. van Breda A, Katzen BT, Deutsch AS. Urokinase versus streptokinase in local thrombolysis. Radiology. 1987;165:109-111.
207. Bell W. Update on urokinase and streptokinase: a comparison of their efficacy and safety. Hospital Formulary. 1988;23:230-241.
208. Janosik JE, Bettmann MA, Kaul AF, Souney PF. Therapeutic alternatives for subacute peripheral arterial occlusion: comparison by outcome, length of stay, and hospital charges. Invest Radiol. 1991; 26:921-925.
209. Lawrence PF, Goodman GR. Thrombolytic therapy. Surg Clin North Am. 1992;72:899-918.
210. Shortell CK, Ouriel K. Thrombolysis in acute peripheral arterial occlusion: predictors of immediate success. Ann Vasc Surg. 1994; 8:59-65.
211. Bookstein JJ, Fellmeth B, Roberts A, Valji K, Davis G, Machado T. Pulsed-spray pharmacomechanical thrombolysis: preliminary clinical results. AJR Am J Roentgenol. 1989;152:1097-1100.
212. Bookstein JJ, Valji K. Pulse-spray pharmacomechanical thrombolysis. Cardiovasc Intervent Radiol. 1992;15:228-233.
213. Kandarpa K, Chopra PS, Aruny JE, Polak JF, Donaldson MC, Whittemore AD, Mannick JA, Goldhaber SZ, Meyerovitz MF. Intraarterial thrombolysis of lower extremity occlusions: prospective, randomized comparison of forced periodic infusion and conventional slow continuous infusion. Radiology. 1993;188:861-867.
214. Ferguson LJ, Faris I, Robertson A, Lloyd JV, Miller JH. Intra-arterial streptokinase therapy to relieve acute limb ischemia. J Vasc Surg. 1986;4:205-210.
215. Belkin M, Donaldson MC, Whittemore AD, Polak JF, Grassi CJ, Harrington DP, Mannick JA. Observations on the use of thrombolytic agents for thrombotic occlusion of infrainguinal vein grafts. J Vasc Surg. 1990;11:289-296.
216. McNamara TO, Bomberger RA, Merchant RF. Intra-arterial urokinase as the initial therapy for acutely ischemic lower limbs. Circulation. 1991;83(suppl I):I-106-I-119.
217. Graor RA, Risius B, Denny KM, Young JR, Beven EG, Hertzer NR, Ruschhaupt WF III, O'Hara PJ, Geisinger MA, Zelch MG. Local thrombolysis in the treatment of thrombosed arteries, bypass grafts, and arteriovenous fistulas. J Vasc Surg. 1985;2:406-414.
218. McNamara TO, Bomberger RA. Factors affecting initial and 6 month patency rates after intraarterial thrombolysis with high dose urokinase. Am J Surg. 1986;152:709-712.
219. Faggioli GL, Ricotta JJ. Thrombolytic therapy for lower extremity arterial occlusion. Ann Vasc Surg. 1993;7:297-302.
220. Durham JD, Geller SC, Abbott WM, Shapiro H, Waltman AC, Walker TG, Brewster DC, Athanasoulis CA. Regional infusion of urokinase into occluded lower-extremity bypass grafts: long-term clinical results. Radiology. 1989;172:83-87.
221. Sullivan KL, Gardiner GA Jr, Shapiro MJ, Bonn J, Levin DC. Acceleration of thrombolysis with a high-dose transthrombus bolus technique. Radiology. 1989;173:805-808.
222. Gardiner GA Jr, Koltun W, Kandarpa K, Whittemore A, Meyerovitz MF, Bettmann MA, Levin DC, Harrington DP. Thrombolysis of occluded femoropopliteal grafts. AJR Am J Roentgenol. 1986;147: 621-626.
223. Rush DS, Gewertz BL, Lu CT, Neely SM, Ball DG, Beasley M, Zarins CK. Selective infusion of streptokinase for arterial thrombosis. Surgery. 1983;93:828-833.
224. Kakkasseril JS, Cranley JJ, Arbaugh JJ, Roedersheimer LR, Welling RE. Efficacy of low-dose streptokinase in acute arterial occlusion and graft thrombosis. Arch Surg. 1985;120:427-429.
225. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: the STILE trial. Ann Surg. 1994;220:251-266.
226. Browse DJ, Tome EP, Galland RB. Early results and 1-year follow-up after intra-arterial thrombolysis. Br J Surg. 1993;80:194-197.
227. Barr H, Lancashire MJ, Torrie EP, Galland RB. Intra-arterial thrombolytic therapy in the management of acute and chronic limb ischaemia. Br J Surg. 1991;78:284-287.
228. Hess H, Ingrisch H, Mietaschk A, Rath H. Local low-dose thrombolytic therapy of peripheral arterial occlusions. N Engl J Med. 1982;307:1627-1630.
229. Italian Cooperative Study Bologna. Endoarterial treatment of acute ischemia of the limbs with urokinase. Int Angiol. 1989;8:53-56.
230. Sicard GA, Schier JJ, Totty WG, Gilula LA, Walker WB, Etheredge EE, Andersen CB. Thrombolytic therapy for acute arterial occlusion. J Vasc Surg. 1985;2:65-78.
231. Nilsson L, Albrechtsson U, Jonung T, Ribbe E, Thorvinger B, Thorne J, Astedt B, Norgren L. Surgical treatment versus thrombolysis in acute arterial occlusion: a randomised controlled study. Ear J Vasc Surg. 1992;6:189-193.
232. Ouriel K, Shortell CK, DeWeese JA, Green RM, Francis CW, Azodo MV, Gutierrez OH, Manzione JV, Cox C, Marder VJ. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg. 1994;19:1021-1030.
233. Decrinis M, Pilger E, Stark G, Lafer M, Obernosterer A, Lammer J. A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: primary and long-term results. Eur Heart J. 1993;14:297-305.
234. Hess H. Thrombolytic therapy in peripheral vascular disease. Br J Surg. 1990;77:1083-1084.
235. Whittemore AD, Donaldson MC, Polak JF, Mannick JA. Limitations of balloon angioplasty for vein graft stenosis. J Vasc Surg. 1991;14:340-345.
236. Sullivan KL, Gardiner GA Jr, Kandarpa K, Bonn J, Shapiro MJ, Carabasi RA, Smullens S, Levin DC. Efficacy of thrombolysis in infrainguinal bypass grafts. Circulation. 1991;83(suppl 1): I-99-I-105.
237. Gardiner GA Jr, Harrington DP, Koltun W, Whittemore A, Mannick JA, Levin DC. Salvage of occluded arterial bypass grafts by means of thrombolysis. J Vasc Surg. 1989;9:426-431.
238. Bull PG, Guttierez E, Mendel H, Schlegl A, Dellinger C. Thrombolysis combined with angioplasty for failed femorodistal arterial grafts. Acta Chir Belg. 1993;93:276-283.
239. Graor RA, Risius B, Young JR, Lucas FV, Beven EG, Hertzer NR, Krajewski LP, O'Hara PJ, Olin J, Ruschhaupt WF. Thrombolysis of peripheral arterial bypass grafts: surgical thrombectomy compared with thrombolysis - a preliminary report. J Vasc Surg. 1988; 7:347-355.
240. Van Breda A. Thrombolysis in arterial bypass grafts. Semin Thromb Hemost. 1991;17:7-13.
241. Karmody AM, Powers SR, Monaco VJ, Leather RP. Blue toe syndrome: an indication for limb salvage surgery. Arch Surg. 1976; 111:1263-1268.
242. The Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery/North American Chapter, International Society for Cardiovascular Surgery. Suggested standards for reports dealing with lower extremity ischemia. J Vasc Surg. 1986;4:80-94.
243. Wilson SE, Wolf GL, Cross AP. Percutaneous transluminal angioplasty versus operation for peripheral arteriosclerosis: report of a prospective randomized trial in a select group of patients, J Vasc Surg. 1989;9:1-9.
244. Howell MA, Colgan MP, Seeger RW, Ramsey DE, Sumner DS. Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity, a six-year follow-up study. J Vasc Surg. 1989;9:691-697.
245. Felix WR Jr, Sigel B, Gunther L. The significance for morbidity and mortality of Doppler-absent pedal pulses. J Vasc Surg. 1987;5: 849-855.
246. Kallero KS, Bergqvist D, Cederholm C, Jonsson K, Olsson PO, Takolander R. Late mortality and morbidity after arterial reconstruction: the influence of arteriosclerosis in the popliteal artery trifurcation. J Vasc Surg. 1985;2:541-546.
247. Malone JM, Moore WS, Goldstone J. Life expectancy after aortofemoral grafting. Surgery. 1977;81:551-555.
248. Taylor LM Jr, Hamre D, Dalman RL, Porter JM. Limb salvage vs amputation for critical ischemia: the role of vascular surgery. Arch Surg. 1991;126:1251-1258.
249. Edwards JE, Taylor LM Jr, Porter JM. Treatment of failed lower extremity bypass grafts with new autogenous vein bypass grafting. J Vasc Surg. 1990;11:136-144.
250. Veith FJ, Gupta SK, Wengerter KR, Goldsmith J, Rivers SP, Bakal CW, Dietzek AM, Cynamon J, Sprayregen S, Gliedman ML. Changing arteriosclerotic disease patterns and management strategies in lower-limb-threatening ischemia. Ann Surg. 1990;212: 402-414.
251. Ouriel K, Fiore WM, Geary JE. Limb-threatening ischemia in the medically compromised patient: amputation or revascularization? Surgery: 1988;104:667-672.
252. De Frang RD, Taylor LM Jr, Porter JM. Basic data related to amputations. Ann Vasc Surg. 1991;5:202-207.
253. Raviola CA, Nichter LS, Baker JD, Busuttil RW, Machleder HI, Moore WS. Cost of treating advanced leg ischemia: bypass graft vs primary amputation. Arch Surg. 1988;123:495-496.
254. Mackey WC, McCullough JL, Conlon TP, Shepard AD, Deterling RA, Callow AD, O'Donnell TF. The costs of surgery for limb-threatening ischemia. Surgery. 1986;99:26-35.
255. Veith FJ, Gupta SK, Samson RH, Scher LA, Fell SC, Weiss P, Janko G, Flores SW, Rifkin H, Bernstein G, Haimovici H, Gliedman ML, Sprayregen S. Progress in limb salvage by reconstructive arterial surgery combined with new or improved adjunctive procedures. Ann Surg. 1981;194:386-401.
256. Cronenwett JL, McDaniel MD, Zwolak RM, Walsh DB, Schneider JR, Reus SF, Colen LB. Limb salvage despite extensive tissue loss: free tissue transfer combined with distal revascularization. Arch Surg. 1989;124:609-615.
257. Gibbons GW, Marcaccio EJ Jr, Burgess AM, Pomposelli FB Jr, Freeman DV, Campbell DR, Miller A, LoGerfo FW. Improved quality of diabetic foot care, 1984 vs 1990: reduced length of stay and costs, insufficient reimbursement. Arch Surg. 1993;128: 576-581.
258. Edwards JM, Taylor LM Jr, Porter JM. Limb salvage in end-stage renal disease (ESRD): comparison of modern results in patients with and without ESRD. Arch Surg. 1988;123:1164-1168.
259. Harrington EB, Harrington ME, Schanzer H, Haimov M. End-stage renal disease: is infrainguinal revascularization justified? J Vasc Surg. 1990;12:691-696.
260. Veith FJ, Gupta SK, Ascer E, White-Flores S, Samson RH, Scher LA, Towne JB, Bernhard VM, Bonier P, Flinn WR. Six-year prospective mullicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg. 1986;3:104-114.
261. Veterans Administration Cooperative Study Group 141. Comparative evaluation of prosthetic, reversed, and in situ vein bypass grafts in distal popliteal and tibial-peroneal revascularization. Arch Surg. 1988;123:434-438.
262. Moody AP, Edwards PR, Harris PL. In situ versus reversed femoropopliteal vein grafts: long-term follow-up of a prospective, randomized trial. Br J Surg. 1992;79:750-752.
263. Watelet J, Cheysson E, Poels D, Menard JF, Papion H, Saour N, Testart J. In situ versus reversed saphenous vein for femoropopliteal bypass: a prospective randomized study of 100 cases. Ann Vasc Surg. 1987;1:441-452.
264. Wengerter KR, Veith FJ, Gupta SK, Goldsmith J, Farrell E, Harris PL, Moore D, Shanik G. Prospective randomized multicenter com- parison of in situ and reversed vein infrapopliteal bypasses. J Vasc Surg. 1991;13:189-199.
265. Aalders GJ, van Vroonhoven TJMV. Polytetrafluoroethylene versus human umbilical vein in above-knee femoropopliteal bypass: six-year results of a randomized clinical trial. J Vasc Surg. 1992;16:816-824.
266. Eickhoff JH, Buchardt Hansen HJ, Bromme A, Ericsson BF, Kordt KF, Mouritzen C, Myhre HO, Norgren L, Rostad H, Trippestad A. A randomized clinical trial of PTFE versus human umbilical vein for femoropopliteal bypass surgery: preliminary results. Br J Surg. 1983;70:85-88.
267. Miyata T, Tada Y, Takagi A, Sato O, Oshima A, Idezuki Y, Shiga J. A clinicopathologic study of aneurysm formation of glutaraldehydetanned human umbilical vein grafts. J Vasc Surg. 1989;10:605-611.
268. Gupta SK, Veith FJ, Kram HB, Wengerter KR. Prospective, randomized comparison of ringed and nonringed polytetrafluoroethylene femoropopliteal bypass grafts: a preliminary report. J Vasc Surg. 1991;13:163-172.
269. Polterauer P, Prager M, Holzenbein T, Karner J, Kretschmer G, Schemper M. Dacron versus polytetrafluoroethylene for Y-aortic bifurcation grafts: a six-year prospective, randomized trial. Surgery. 1992;111:626-633.
270. De Mol van Otterloo JC, Van Bockel JH, Ponfoort ED, Van den Akker PJ, Hermans J, Terpstra JL. Randomized study on the effect of collagen impregnation of knitted Dacron velour aortoiliac prostheses on blood loss during aortic reconstruction. Br J Surg. 1991;78:288-292.
271. Robicsek F, Duncan GD, Daugherty HK, Cook JW, Selle JG, Hess PJ, Lawhorn R. 'Half and half woven and knitted Dacron grafts in the aortoiliac and aortofemoral positions: seven and one-half years follow-up. Ann Vasc Surg. 1991;5:315-319.
272. Passman MA, Taylor LM, Moneta GL, Edwards JM, Yeager RA, McConnell DB, Porter JM. Comparison of axillofemoral and aortofemoral bypass for aortoiliac occlusive disease. J Vasc Surg. 1996;23:263-271.
273. Quinones-Baldrich WJ, Busuttil RW, Baker JD, Vescera CL, Ahn SS, Machleder HI, Moore WS. Is the preferential use of polytetrafluoroethylene grafts for femoropopliteal bypass justified? J Vasc Surg. 1988;8:219-228.
274. Whittemore AD, Kent KC, Donaldson MC, Couch NP, Mannick JA. What is the proper role of polytetrafluoroethylene grafts in infrainguinal reconstruction? J Vasc Surg. 1989;10:299-305.
275. Londrey GL, Ramsey DE, Hodgson KJ, Barkmeier LD, Sumner DS. Infrapopliteal bypass for severe ischemia: comparison of autogenous vein, composite, and prosthetic grafts. J Vasc Surg. 1991; 13:631-636.
276. Berlakovich GA, Herbst F, Mittlbock M, Kretschmer G. The choice of material for above- knee femoropopliteal bypass: a 20-year experience. Arch Surg. 1994;129:297-302.
277. Sterpetti AV, Schultz RD, Feldbaus RJ, Peetz DJ Jr. Seven-year experience with polytetrafluoroethylene as above-knee femoropopliteal bypass graft. Is it worthwhile to preserve the autologous saphenous vein? J Vasc Surg. 1985;2:907-912.
278. Taylor LM Jr, Porter JM. Clinical and anatomic considerations for surgery in femoropopliteal disease and the results of surgery. Circulation. 1991;83(suppl I):I-63-I-69.
279. Kent KC, Whittemore AD, Mannick JA. Short-term and midterm results of an all- autogenous tissue policy for infrainguinal reconstruction. J Vasc Surg. 1989;9:107-114.
280. Harris RW, Andros G, Dulawa LB, Oblath RW, Salles-Cunha SX, Apyan R. Successful long-term limb salvage using cephalic vein bypass grafts. Ann Surg. 1984;200:785-792.
281. Chang BB, Paty PSK, Shah DM, Leather RP. The lesser saphenous vein: an underappreciated source of autogenous vein. J Vasc Surg. 1992;15:152-157.
282. Schulman ML, Badhey MR, Yatco R, Pillari G. An 11-year experience with deep leg veins as femoropopliteal bypass grafts. Arch Surg. 1986;121:1010-1015.
283. Taylor LM Jr, Edwards JM, Porter JM. Present status of reversed vein bypass grafting: five-year results of a modern series. J Vasc Surg. 1990;11:193-206.
284. Taylor RS, Loh A, McFarland RJ, Cox M, Chester JF. Improved technique for polytetrafluoroethylene bypass grafting: long-term results using anastomotic vein patches, Br J Surg. 1992;79: 348-354.
285. Bartlett ST, Olinde AJ, Flinn WR, McCarthy WJ III, Fahey VA, Bergan JJ, Yao JS. The reoperative potential of infrainguinal bypass: long-term limb and patient survival. J Vasc Surg. 1987;5: 170-179.
286. Szilagyi DE, Elliott JP, Hageman JH, Smith RF, Dall'olmo CA. Biologic fate of autogenous vein implants as arterial substitutes: clinical, angiographic and histopathologic observations in femoro-popliteal operations for atherosclerosis. Ann Surg. 1973; 178:232-246.
287. Hobson RW. Recurrent symptoms and vein graft stenosis: the failing graft. In: Brewster DC, ed. Common Problems in Vascular Surgery. Chicago, Ill: Year Book Medical Publishers Inc; 1989: 289-293.
288. Mills JL, Harris EJ, Taylor LM Jr, Beckett WC, Porter JM. The importance of routine surveillance of distal bypass grafts with duplex scanning: a study of 379 reversed vein grafts. J Vasc Surg. 1990;12:379-389.
289. Nehler MR, Moneta GL, Yeager RA, Edwards JM, Taylor LM Jr, Porter JM. Surgical treatment of threatened reversed infrainguinal vein grafts. J Vasc Surg. 1994;20:558-563.
290. Szilagyi DE, Elliott JP Jr, Smith RF, Reddy DJ, McPharlin M. A thirty-year survey of the reconstructive treatment of aortoiliac occlusive disease. J Vasc Surg. 1986;3:421-436.
291. Taylor LM Jr, Moneta GL, McConnell D, Yeager RA, Edwards JM, Porter JM. Axillofemoral grafting with externally supported polytetrafluoroethylene. Arch Surg. 1994;129:588-594.
292. Inahara T. Evaluation of endarterectomy for aortoiliac and aortoiliofemoral occlusive disease. Arch Surg. 1975;110:1458-1464.
293. Dalman RL, Taylor LM Jr, Moneta GL, Yeager RA, Porter JM. Simultaneous operative repair of multilevel lower extremity occlusive disease. J Vasc Surg. 1991;13:211-221.
294. Dalman RL, Taylor LM Jr. Basic data related to infrainguinal revascularization procedures. Ann Vasc Surg. 1990;4:309-312.